Implicity, a European leader in remote monitoring of implantable cardiac devices and remote patient monitoring, announced at the end of April, a series A fundraising of 21 million euros from Crédit Mutuel Innovation and Bpifrance, as well as BNP Paribas Development and historical investors Serena Capital, XAnge and Karista. This investment will allow it, on the one hand, to accelerate the deployment of its AI-based technology and, on the other hand, to develop new medical software..
A MedTech digital startup in the cardiology sector, Implicity aims to improve the efficiency of remote heart monitoring and democratize it. Co-founded by Arnaud Rosier, electrophysiologists and physicians in health informatics, convinced that remote monitoring can improve patient care and provide them with an optimized vital prognosis, and David Perlmutter in 2016, signal processing engineer, currently responsible for R&D.
Implicity now leads the remote monitoring of implantable cardiac electronic devices (ICED) in France and around the world, thanks to its remote monitoring platform covering more than 60,000 patients in 100 medical establishments in Europe and the United States. . The winner of the first Health Data Hub called for projects providing access to the Health Data Club’s health database as well as the National Health Data System, Implicity has developed medical device software based on artificial intelligence algorithms for predictive cardiology and to optimize medical functioning. teams.
The start-up also recently received authorization from the FDA (Federal and Drug Administration), the U.S. federal agency for food, drugs, and medical devices, to take advantage of a new AI algorithm intended to test the episodes. ECG of implantable cardiac monitors.
Arnaud Rosier explained:.
“This rounding of funding opens an exciting new chapter for Implicity. As we see everywhere that remote monitoring teams are grappling with increasing data from connected devices, the need for a universal remote platform is widely recognized as the most important for everyone in the field.With the support of investors, we plan to increase our presence in the United States and expand new market opportunities.To democratize remote heart care , our mission is to provide healthcare professionals with the best technology available to follow all heart patients. »
Develop new software for medicine and accelerate international deployment
This fundraiser will accelerate the global deployment of Implicity’s AI-based technology, specifically in the United States, but also to develop new medical device software, and thus allow Simplicity to maintain the position. its leadership. .
Delphine Cardi, investment director at Crédit Mutuel innovation, assures:
“We are very pleased to support the commercial expansion of the Implicity remote monitoring platform that enables cardiologists to offer their patients better quality follow-up thanks to a creative integration of data from remote cardiac monitoring device. The company is on a solid growth trajectory in the United States and Europe. With this investment, we are giving it a way to continue its momentum and build next-generation offerings focused on heart disease prevention. »
Chahra Louafi, Director of the Autonomous Patients Fund at Bpifrance added:
“We are impressed with Implicity’s current success in the international market. We believe the company has the potential to become a world-class leader in remote heart monitoring. This investment will help accelerate adoption. all regions in 2022, especially in the United States which is a huge market opportunity. »